Your request has been received.
We will send you more information as it becomes available.
days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
Only EXPAREL provides long-lasting pain control in a single dose.
pMVL provides a sustained release of bupivacaine over time, maintaining plasma levels below toxic thresholds in various nerve blocks5-7
209.35 ng/mL5
EXPAREL 133 mg ISBPNB
381.62 ng/mL7
EXPAREL 133 mg Sciatic Popliteal Block
CNS, central nervous system; FNB, femoral nerve block; ISBPNB, interscalene brachial plexus nerve block; LB, liposomal bupivacaine; pMVL, proprietary multivesicular liposome technology; TKA, total knee arthroplasty.
$376.12
266 mg (20 mL)
$227.63
133 mg (10 mL)
Continuous catheter
Average of $433.82 per patient for device alone8
One EXPAREL 266 mg (20 ml) single-use vial may require only one vial of bupivacaine‡
-OR-
Less than one vial of
bupivacaine when one EXPAREL 133 mg (10 ml) single-use vial is used in an interscalene brachial plexus nerve
vs
Continuous catheters require up to
10 to 15 vials of bupivacaine
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.